Case report · 10 Aug 2026
Conference abstractPublished 16 Jul 2018
Toxicity study of poly-herbal formulation in Wistar rats
B. K. Mody Government Pharmacy College, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The renowned eight herbs considered in the use of traditional system of medicine for the treatment of piles are the main constituents of the Pile Relief Formulation (PRF). Every single herb is proven as a safest drug but the effects are yet not identified when they are used in combination with each other. Hence, the present investigation is carried out to elucidate toxicological profile of PRF in rats in terms of acute and sub-acute oral toxicity. The OECD guidelines 420 and 407 were used to perform acute and sub-acute oral toxicity study respectively. In case of acute toxicity study, single 2000 mg/kg oral dose of PRF was administered in female albino Wistar rats, while for sub-acute oral toxicity study various dose like 50, 250 and 500 mg/kg daily for 28 days were administered in both male and female albino Wistar rats. The effect of PRF on body weight, relative organ weights (liver, kidney, lung, heart, brain), biochemical (cholesterol, triglyceride, urea, creatinine, AST, ALT, bilirubin, protein, uricacid, RBS), hematological (RBC, WBC, HB, Monocytes, lymphocytes, eosinophils, PCV, MCV, MCH, MCHC, PLT) and histopathological parameters were characterized. No mortality or behavioral changes in rats treated with single dose of 2000 mg/kg was observed so PRF is considered to be safe at this dose. No significant changes in body weight, relative organ weights, biochemical, hematological and histopathological parameters with three different dose levels were observed in sub-acute toxicity study for 28 days. The result clearly demonstrated the absence of acute and sub-acute oral toxicity of PRF in order to prove safety evidence for its use in animals. However, further animal and clinical experiments are needed for safety and efficacy of the pile relief.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Trials.
Short communication · 31 Jul 2026
Understanding Bioavailability as a Key Element in Effective Therapeutic Delivery
Research article · 14 Jun 2026
Ensuring Rights and Dignity in Ethical Practices of Clinical Studies with Vulnerable Group and Safeguarding Vulnerable Group Act (2006)
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Trials
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Divya Pradipbhai Maheta”
- BylineArticles whose byline prints “Ravi Manek”
- BylineArticles whose byline prints “Sheth Devang”
